Bonk, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $12.2M
- Price
- $1.53
- % Change (Daily % change from the live per-ticker quote feed.)
- -12.57%
- Volume
- 252.3K
About
Operating from its headquarters in Jupiter, Florida, Safety Shot, Inc. supplies a variety of consumer goods across the United States, including numerous over-the-counter (OTC) remedies. A primary product is their "Safety Shot Beverage," an OTC drink specifically formulated to reduce blood alcohol levels. The company's diverse portfolio also features treatments for hair thinning, vitiligo solutions, eczema creams, and a range of sexual wellness items. These products reach customers through various channels, encompassing direct sales, partnerships with distributors and retailers, and online e-commerce platforms. Established in 2018, the entity previously operated as Jupiter Wellness, Inc. before officially adopting the name Safety Shot, Inc. in September 2023.
Quick stats
Shares outstanding8.0M
Computed float7.8M
Float / shares97.1%
Key info
SectorConsumer Defensive
IndustryBeverages - Non-Alcoholic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001760903
Websitehttps://www.bonkdat.com
AI Summary
AI-generated1/12
standardbullishbuyback
Bonk, Inc. Announces $4.0 Million Preferred Stock Redemption and Anti-Dilution Waiver
Bonk, Inc. has agreed to purchase and retire 26,667 shares of its Series A Preferred Stock from Core4 Capital Holdings for an aggregate price of $4.0 million, directly cutting senior preferred overhang by more than 26%.
As part of the consideration, Core4 irrevocably waived all anti-dilution rights on its preferred holdings, including full-ratchet and weighted-average provisions, removing a legacy structural dilution threat to common shareholders.
Core4's preferred stake falls from 100,000 to 73,333 shares, which would convert into 1,516,873 common shares in a merger, and Core4 granted a comprehensive release of all legacy claims against the company.
Management framed the redemption as a decisive capital structure cleanup intended to improve institutional appeal and preserve flexibility for accretive M&A.
Red flags
- Consumes $4.0M of cash at a micro-cap holding company with no stated funding source for the payment
- Core4 retains 73,333 preferred shares that convert into 1,516,873 common shares in a merger — residual dilution overhang remains
- Redemption pricing basis versus preferred stated/liquidation value is not disclosed in the release